Literature DB >> 15210796

Serine residues 286, 288, and 293 within the CIITA: a mechanism for down-regulating CIITA activity through phosphorylation.

Susanna F Greer1, Jonathan A Harton, Michael W Linhoff, Christin A Janczak, Jenny P-Y Ting, Drew E Cressman.   

Abstract

CIITA is the primary factor activating the expression of the class II MHC genes necessary for the exogenous pathway of Ag processing and presentation. Strict control of CIITA is necessary to regulate MHC class II gene expression and induction of an immune response. We show in this study that the nuclear localized form of CIITA is a predominantly phosphorylated form of the protein, whereas cytoplasmic CIITA is predominantly unphosphorylated. Novel phosphorylation sites were determined to be located within a region that contains serine residues 286, 288, and 293. Double mutations of these residues increased nuclear CIITA, indicating that these sites are not required for nuclear import. CIITA-bearing mutations of these serine residues significantly increased endogenous MHC class II expression, but did not significantly enhance trans-activation from a MHC class II promoter, indicating that these phosphorylation sites may be important for gene activation from intact chromatin rather than artificial plasmid-based promoters. These data suggest a model for CIITA function in which phosphorylation of these specific sites in CIITA in the nucleus serves to down-regulate CIITA activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15210796     DOI: 10.4049/jimmunol.173.1.376

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Phosphorylation and ubiquitination of degron proximal residues are essential for class II transactivator (CIITA) transactivation and major histocompatibility class II expression.

Authors:  Kavita Purnanda Bhat; Agnieszka Dorota Truax; Susanna Fletcher Greer
Journal:  J Biol Chem       Date:  2010-06-10       Impact factor: 5.157

Review 2.  Towards a systems understanding of MHC class I and MHC class II antigen presentation.

Authors:  Jacques Neefjes; Marlieke L M Jongsma; Petra Paul; Oddmund Bakke
Journal:  Nat Rev Immunol       Date:  2011-11-11       Impact factor: 53.106

3.  Human cytomegalovirus decreases constitutive transcription of MHC class II genes in mature Langerhans cells by reducing CIITA transcript levels.

Authors:  Andrew W Lee; Nan Wang; Tara M C Hornell; James J Harding; Chetan Deshpande; Laura Hertel; Vashti Lacaille; Achal Pashine; Claudia Macaubas; Edward S Mocarski; Elizabeth D Mellins
Journal:  Mol Immunol       Date:  2011-03-31       Impact factor: 4.407

Review 4.  Structural aspects of the MHC expression control system.

Authors:  Grady Nash; Bhaskar Paidimuddala; Liman Zhang
Journal:  Biophys Chem       Date:  2022-02-15       Impact factor: 2.352

5.  Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun.

Authors:  Daejin Kim; Talia Hoory; Archana Monie; Jenny Pan-Yun Ting; Chien-Fu Hung; T-C Wu
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

6.  The IFN-gamma-induced transcriptional program of the CIITA gene is inhibited by statins.

Authors:  Sun J Lee; Hongwei Qin; Etty N Benveniste
Journal:  Eur J Immunol       Date:  2008-08       Impact factor: 5.532

7.  Stable protein, unstable plaque?

Authors:  Nicholas E S Sibinga
Journal:  J Mol Cell Cardiol       Date:  2008-12-03       Impact factor: 5.000

8.  Transcriptional coactivator CIITA, a functional homolog of TAF1, has kinase activity.

Authors:  Katherine C Soe; Ballachanda N Devaiah; Dinah S Singer
Journal:  Biochim Biophys Acta       Date:  2013-09-13

9.  Mitogen-activated protein kinase ERK1/2 regulates the class II transactivator.

Authors:  Lilien N Voong; Allison R Slater; Sebila Kratovac; Drew E Cressman
Journal:  J Biol Chem       Date:  2008-02-01       Impact factor: 5.157

Review 10.  Regulating the activity of class II transactivator by posttranslational modifications: exploring the possibilities.

Authors:  Xiaoyan Wu; Xiaocen Kong; Larry Luchsinger; Barbara D Smith; Yong Xu
Journal:  Mol Cell Biol       Date:  2009-08-31       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.